Código QR (código de barras bidimensional)

Addition of daratumumab to standard triplet regimens achieved better survival in newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials

BackgroundTriplet regimens, such as bortezomib-lenalidomide-dexamethasone (VRd) and bortezomib-melphalan-prednisone (VMP), were standard treatments for newly diagnosed multiple myeloma (NDMM), but they were non-curative for most patients. The incorporation of daratumumab into these regimens, resulti...

ver descrição completa

Na minha lista:
Principais autores: Bin Hu, Jun Wang, Dan Fang, Ling Jiang, Tianqi Li, Jinxia Cao
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2025-10-01
coleção:Frontiers in Oncology
Assuntos:
daratumumab
quadruplet regimens
triplet regimens
multiple myeloma
meta-analysis
Acesso em linha:https://www.frontiersin.org/articles/10.3389/fonc.2025.1619115/full
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados